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Primary systemic arterial
vasodilation in cirrhotic patients
To the Editor: The increased plasma volume in cirrhotic
patients with ascites made untenable the ‘underﬁll hypothesis’
secondary to ascites-mediated diminished plasma volume.
Thus, the ‘overﬂow hypothesis’ was proposed in which a
hepatic–renal reﬂex caused renal sodium retention with
resultant plasma and extracellular ﬂuid (ECF) expansion.
The ECF expansion then increases cardiac output and causes
secondary systemic arterial vasodilation. In a recent review
in Kidney International,1 a ﬁgure from an experimental
study supports secondary arterial vasodilation in cirrhosis.1
However, another experimental study demonstrated that
prehepatic portal hypertension caused primary systemic vaso-
dilation followed by increased total body sodium.2
Primary systemic arterial vasodilation, as occurs early in
the splanchnic circulation in cirrhosis, must be distinguished
from ECF volume expansion causing increased cardiac output
and secondary systemic arterial vasodilation (overﬂow
hypothesis). With secondary arterial vasodilation due to
ECF volume expansion blood pressure should be increased or
remain normal because of suppression of the neurohumoral
axis including plasma norepinephine (NE), renin-angioten-
sin-aldosterone system (RAAS), and arginine vasopressin
(AVP). However, as cirrhotic patients progress from compen-
sated to decompensated to hepatorenal syndrome (HRS),
there is a progressive decline in systemic vascular resistance
and decreased blood pressure. Moreover, there is a progres-
sive rise in plasma NE, plasma renin activity, and AVP with
resultant hyponatremia during progression of cirrhosis to
HRS, all known risk factors for increased mortality in
cirrhosis.3 Thus, the ‘primary systemic arterial vasodilation
hypothesis’ causing arterial underﬁlling (Figure 1) has been
proposed to explain the pathogenesis of renal sodium and
water retention in cirrhotic patients.4
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on our review in which we proposed2 that the stimulus
initiating and maintaining salt retention in cirrhosis is located
in the liver (that is, in a hepatic ‘volume’ sensor). Dr Schrier
suggests that the syndrome of worsening extracellular ﬂuid
volume (ECFV) expansion plus low blood pressure and
activation of the neuro-humoral axis of ECFV control in
advanced cirrhosis and hepatorenal syndrome is best
attributed to primary systemic vasodilation because secondary
vasodilation due to ECFV expansion would not lower blood
pressure plus would suppress the neuro-humoral axis, and
Albillos et al.3 found systemic vasodilation before sodium
retention in portal hypertension. Although the hemodynamic
and neuro-humoral response to ECFV expansion in normal
conditions would be as he stated, there is no a priori reason
why it should be the same in diseases where homeostatic
responses to abnormal stimuli frequently cause unpredictable
changes. Indeed, patients with congestive heart failure due to
obstructive pulmonary disease4 and patients with edema due
to severe chronic anemia,5 have ECFV expansion, low blood
pressure, systemic vasodilation and activated neuro-humoral
axis of ECFV control. A similar phenotype is also found in
pregnancy wherein the reason for it also remains unex-
plained.6–8 Concerning the study of Albillos et al.,3 leaving
aside the experimental difﬁculties in accurately measuring
systemic hemodynamics in anesthetized rodents, these work-
ers constricted the portal vein and thus created a model quite
different from cirrhosis. In sum, we believe that the available
evidence best supports the presence of a hepatic ‘volume’
sensor that is pathologically activated during cirrhosis and
that systemic vasodilation is a secondary phenomena. None-
theless, we agree with Dr Schrier’s underlying point that the
current understanding of the stimulus that drives salt
retention in cirrhosis is still in the hypothesis stage.1 Clearly,
experimental work to resolve this issue is urgently needed.
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Figure 1 |Primary systemic arterial vasodilation.
*Not suppressed in spite of plasma volume expansion.
(Schrier RW et al.4)
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Only anti-CD133 antibodies
recognizing the CD133/1 or the
CD133/2 epitopes can identify
human renal progenitors
To the Editor: Ivanova et al.1 describe the expression of
CD24 and CD133 in developing human kidneys. Their study is
based on our previous reports, showing the existence of
a CD24þCD133þ renal progenitor population in human
kidney.2,3 In agreement with our results, they show that CD24 is
a reliable marker to detect and purify human renal progenitors,
whereas they are unable to obtain a further enrichment of
human renal progenitors using CD133 as an additional marker,
as we previously reported.2,3 However, Ivanova et al. used anti-
CD133 polyclonal antibodies, which stained diffusely differ-
entiated epithelial structures in embryonic, as well as adult
kidneys.1 By contrast, we used anti-CD133 monoclonal
antibodies recognizing CD133/1 (clone AC133) or CD133/2
(clone 293C3) epitopes, which selectively recognized renal
progenitors.2,3 It is common knowledge in the stem-cell ﬁeld
that only anti-CD133/1 or anti-CD133/2 antibodies can be used
to detect and purify stem cells in several human tissues, whereas
other anti-CD133 antibodies show expression in differentiated
cells.4 Recent studies have clariﬁed this apparent discrepancy.5
Indeed, different tertiary structures of the CD133 molecule
justify the diverse accessibility of the CD133/1 or CD133/2
epitopes in undifferentiated versus differentiated cells.5 Differ-
ential recognition of CD133 mRNA variants has also been
suggested.4 Consistently, double-label immunoﬂuorescence per-
formed with anti-CD133 antibodies used by Ivanova et al. and
anti-CD133/1 or anti-CD133/2 antibodies, conﬁrmed that only
the latter recognized human renal progenitors (Figure 1). Thus,
we recommend the usage anti-CD133/1 or CD133/2 antibodies
to detect or purify human renal progenitors.
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Figure 1 |Only antibodies recognizing the CD133/1 or CD133/2
epitopes can identify human renal progenitors. (a, b)
Double-label immunofluorescence performed with the anti-CD133
polyclonal antibody used by Ivanova et al. (pCD133, red) and
the anti-CD133/2 monoclonal antibody (green) in embryonic
human kidneys. The anti-CD133 antibody used by Ivanova et al.
poorly stains primary vesicles, comma-shaped bodies and S-
shaped bodies, while it extensively stains differentiated tubular
cells as well as the differentiating ureteric bud (red). By contrast,
the anti-CD133/2 antibody (green) selectively stains condensed
mesenchyme-derived primordial structures, primary vesicles,
comma-shaped bodies, S-shaped bodies and, in maturing
glomeruli, the urinary pole of the Bowman’s capsule (arrows).
In (b), asterisk indicates a maturing glomerulus. Merged areas
appear in yellow. Topro-3 counterstains nuclei (blue). Bar 100mm.
(b0) Split image of the maturing glomerulus identified by the
asterisk in (b). The arrow indicates the urinary pole of the
Bowman’s capsule. Bar 50mm (c) Double label immuno-
fluorescence performed with the anti-CD133 polyclonal antibody
used by Ivanova et al. (pCD133, red) and the anti-CD133/1
monoclonal antibody (green) in embryonic human kidneys.
Only CD133/1 antibody selectively stains human progenitors of
the Bowman’s capsule (arrow). Merged areas appear in yellow.
Topro-3 counterstains nuclei (blue). Bar 100mm.
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